Background
==========

Breast cancer is one of the most common cancers among women, and is the leading cause of cancer death in this group \[[@b1-medscimonit-22-4121],[@b2-medscimonit-22-4121]\]. Although advances have recently been made in tumor diagnostic and therapeutic strategies, the clinical outcomes of the patients are still poor due to the metastasis and heterogeneity of the cancer \[[@b3-medscimonit-22-4121],[@b4-medscimonit-22-4121]\]. Therefore, there is a need to develop biomarkers that can be used as valuable tools in identifying high-risk patients and to predict disease prognosis \[[@b5-medscimonit-22-4121]\]. The genes that are expressed abnormally during tumor progression and metastasis may be used as markers to provide prognostic information beyond standard clinical assessment \[[@b6-medscimonit-22-4121],[@b7-medscimonit-22-4121]\].

The POU class 1 homeobox 1 transcription factor (*POU1F1*, also known as *Pit-1*) was originally detected in the pituitary gland; it can regulate cell differentiation and is an activator for pituitary gene transcription during organogenesis \[[@b8-medscimonit-22-4121],[@b9-medscimonit-22-4121]\]. In *Pit-1-*deficient mouse models, there were no somatotropes, lactotropes, or thyrotropes generated, leading to anterior pituitary hypoplasia and dwarfism \[[@b10-medscimonit-22-4121]\]. *Pit-1* was also detected in other cell lines and tissues, such as human placenta \[[@b11-medscimonit-22-4121]\], human breast adenocarcinoma cell line \[[@b12-medscimonit-22-4121],[@b13-medscimonit-22-4121]\], and hemopoietic and lymphoid tissues \[[@b14-medscimonit-22-4121]\]. Moreover, abnormal expression of *Pit-1* in these tissues was reported to be associated with tumor progression \[[@b15-medscimonit-22-4121]--[@b17-medscimonit-22-4121]\]. In breast cancer cells, *Pit-1* was reported to be associated with tumor growth and metastasis \[[@b18-medscimonit-22-4121]\], but the prognostic value of *Pit-1* in breast cancer had not been reported yet.

In this study we aimed to evaluate the prognostic significance of *Pit-1* in breast cancer.

Material and Methods
====================

Patients and specimens
----------------------

We enrolled 106 female patients with invasive breast cancer confirmed by clinical and pathological diagnoses in Linyi People's Hospital from October 2008 to January 2015. Tumor tissues and adjacent normal tissues of the patients were immediately stored in liquid nitrogen, then kept at −80°C until use. None of the patients had received any chemotherapy or radiotherapy before the surgery.

The study was approved by the Institutional Research Ethics Committee and complies with the precepts of the Helsinki Declaration. All examinations were performed after obtaining written informed consent from the participants. All the patients were enrolled in a 5-year investigation and the clinical characteristics and survival status of the patients during the follow-up were collected for analyzing the clinical significance of *Pit-1*.

Total RNA extraction and quantitative real-time PCR (qRT-PCR)
-------------------------------------------------------------

Total RNA were extracted from the tumor tissues and corresponding normal tissues using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. DNase was used to deal with the residuary DNA in RNA samples. The concentration of RNA was detected by UV absorbance (A260/A280) and 1% agarose gel electrophoresis was used for evaluating the quality of RNA.

The Prime Scrip RT reagent kit (Takara, Biotechnology Co., Ltd) was used for synthesizing cDNA and qRT-PCR was performed in triplicate with SYBR Premix Ex Taq™ II (TaKaRa). β-actin was used for internal reference. The data were analyzed by 2^−ΔΔCt^ method.

Statistical analysis
--------------------

All the statistical analyses were performed using SPSS 18.0 software (SPSS Inc, IL, USA). The difference of *Pit-1* expression in tumor tissues and normal tissues were analyzed by the *t* test and the results are shown as mean ± standard deviation (SD). The relationship between *Pit-1* expression and the clinical features of breast cancer patients was estimated by chi-square analysis. Kaplan-Meier method was used for evaluating the overall survival of the patients at different levels of *Pit-1*. The prognostic value of *Pit-1* was analyzed by Cox regression analysis. *P*\<0.05 was considered to be statistically significant.

Results
=======

Increased expression of Pit-1 in breast cancer tissues
------------------------------------------------------

Relative expression of *Pit-1* was detected by qRT-PCR. The expression level of *Pit-1* in tumor tissues was 1.086±0.149, while the expression in the normal tissues was 0.541±0.238. The difference in *Pit-1* expression between breast cancer tissue and normal tissue was statistically significant (*P*=0.000), as shown in [Figure 1](#f1-medscimonit-22-4121){ref-type="fig"}.

Correlation between *Pit-1* expression and clinicopathologic characteristics of breast cancer patients
------------------------------------------------------------------------------------------------------

The clinical characteristics of the patients are summarized in [Table 1](#t1-medscimonit-22-4121){ref-type="table"}. The patients were divided into 2 groups based on the average expression level of *Pit-1*. The chi-square test was used to analyze the relationship between *Pit-1* expression and the clinical features. The results suggested that *Pit-1* level was associated with tumor size (*P*=0.03), clinical stage (*P*=0.046), tumor grade (*P*=0.009), and lymph node metastasis (*P*=0.013), but was not significantly correlated with other clinical features such as age and pathology (*P*\>0.05 for all).

Association of *Pit-1* expression with prognosis in breast cancer patients
--------------------------------------------------------------------------

The association between *Pit-1* expression and survival of breast cancer patients was investigated by Kaplan-Meier method. The results indicated that patients with low levels of *Pit-1* had a longer survival time than those with high levels of *Pit-1* (43.4 months *vs.* 32.7 months, log-rank test, *P*=0.001, [Figure 2](#f2-medscimonit-22-4121){ref-type="fig"}). Univariate analysis indicated that *Pit-1* was associated with breast cancer prognosis (*P*=0.001, [Table 2](#t2-medscimonit-22-4121){ref-type="table"}) and multivariate analysis suggested that *Pit-1* was an independently prognostic factor in breast cancer (HR=1.955, 95% CI=1.259--3.035, *P*=0.003, [Table 2](#t2-medscimonit-22-4121){ref-type="table"}).

Discussion
==========

*Pit-1* is one of the first-identified members of the homeodomain-containing proteins, which act as transcriptional regulators determining the fate of cells \[[@b16-medscimonit-22-4121]\]. *Pit-1* was reported to take part in several types of cancer. Palmieri et al. reported that *Pit-1* plays a key role in pituitary gland development and physiology, acting as a transcriptional factor that regulates the gene expression of *Gh*, *Prl*, *Ghrhr,* and *Pit-1* itself \[[@b19-medscimonit-22-4121]\]. In the study of Costoya et al., increased expression level of *Pit-1* was found in exponentially growing human myeloid leukemic cells, and the level was specifically associated with cell proliferation \[[@b16-medscimonit-22-4121]\]. Recently, a number of studies have indicated that *Pit-1* plays an important role in breast cancer cells \[[@b12-medscimonit-22-4121],[@b13-medscimonit-22-4121],[@b17-medscimonit-22-4121],[@b20-medscimonit-22-4121],[@b21-medscimonit-22-4121]\], but the clinical significance of *Pit-1* in breast cancer patients had rarely been reported.

Relative expression of *Pit-1* in tumor tissues and corresponding normal tissues of 106 breast cancer patients were detected in the present study. The results suggest that *Pit-1* is highly expressed in tumor tissues compared with normal tissues. The increased expression pattern suggests that *Pit-1* might play an oncogenic role in breast cancer. Moreover, the abnormal expression was associated with tumor size, tumor grade, clinical stage, and lymph node metastasis. These findings indicate that *Pit-1* is associated with breast cancer progression.

The molecular biomarkers for breast cancer prognosis have been reported in many studies. Yeh et al. reported that granulin is an important prognostic biomarker and potential therapeutic target in breast cancer \[[@b22-medscimonit-22-4121]\]. Fu et al. indicated that SRY-related HMG-box (*SOX17*) is associated with breast cancer progression and can act as a useful prognostic biomarker \[[@b23-medscimonit-22-4121]\]. Pelkonen et al. claimed that *hepsin* and *TMPRSS3* can serve as prognostic markers in breast cancer \[[@b24-medscimonit-22-4121]\]. In addition, Jones et al. \[[@b25-medscimonit-22-4121]\] explored the effects of increased estrogen levels as risk factors of breast cancer in African American women. In the study of Liang et al. \[[@b26-medscimonit-22-4121]\], serum soluble E-cadherin was proved to be an independent prognostic factor in Asian breast cancer patients. Other molecules, such as karyopherin α-2 (*KPNA2*), *HER3*, *PTEN*, *p-HER2*, *P13K*, and *VEGFR-2,* have also emerged as prognostic factors in breast cancer \[[@b27-medscimonit-22-4121],[@b28-medscimonit-22-4121]\]. In the present study, searched for additional molecular markers to better predict and improve the prognosis of breast cancer patients. Our results show that high levels of *Pit-1* are significantly associated with poor overall survival of breast cancer patients, and *Pit-1* could serve as an independent indicator for breast cancer prognosis.

Conclusions
===========

*Pit-1* expression is associated with breast cancer progression. *Pit-1* may be a potential predictor for breast cancer prognosis and a target for treatments.

**Source of support:** Departmental sources
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![Overall survival of breast cancer patients. Patients with high levels of *Pit-1* had a shorter overall survival time (red line), while those with low levels of *Pit-1* showed a longer overall survival (black line). There was a significant difference between groups (log-rank test, *P*=0.001).](medscimonit-22-4121-g002){#f2-medscimonit-22-4121}

###### 

Association between *Pit-1* expression and clinical characteristics of breast cancer patients.

  Characteristics         Total number (n)   *Pit-1* expression   χ^2^   *P*     
  ----------------------- ------------------ -------------------- ------ ------- -------
  Age                                                                    1.691   0.193
   ≥45                    88                 39                   49             
   \<45                   18                 11                   7              
  Tumor size                                                             8.740   0.03
   ≥5 cm                  50                 16                   34             
   \<5 cm                 56                 34                   22             
  Clinical stage                                                         3.982   0.046
   Early                  57                 32                   25             
   Advanced               49                 18                   31             
  Pathology                                                              0.968   0.325
   IDC                    54                 28                   26             
   ILC                    52                 22                   30             
  Tumor grade                                                            6.739   0.009
   Early                  58                 34                   24             
   Advanced               48                 16                   32             
  Lymph node metastasis                                                  6.121   0.013
   Yes                    60                 22                   38             
   No                     46                 28                   18             

###### 

Cox regression analysis.

  Characteristic                         Univariate analysis   Multivariate analysis                                  
  -------------------------------------- --------------------- ----------------------- ------- ------- -------------- -------
  Pit-1 (high *vs.* low)                 2.033                 1.313--3.148            0.001   1.955   1.259--3.035   0.003
  Age (≥45 *vs.* \<45)                   1.116                 0.740--1.685            0.600   1.032   0.673--1.582   0.365
  Tumor size (≥5 *vs.* \<5)              1.212                 0.793--1.854            0.375   1.224   0.790--1.895   0.365
  Clinical stage (III+IV *vs.* I+II)     1.293                 0.855--1.594            0.223   1.229   0.799--1.890   0.349
  Pathology (IDC *vs.* ILC)              0.901                 0.597--1.362            0.622   1.106   0.724--1.690   0.640
  Tumor grade (III *vs.* I+II)           1.224                 0.811--1.848            0.336   1.240   0.813--1.893   0.318
  Lymph node metastasis (yes *vs.* no)   1.347                 0.888--2.044            0.161   1.326   0.869--2.022   0.191
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